Neurogene Inc. (NGNE), a clinical-stage biotechnology company developing gene therapies for rare neurological diseases, demonstrates a permissible core business under Shariah principles but faces significant financial screening challenges. High liquidity (75.3%) and interest income ratio (806.59%) driven by pre-revenue status and cash holdings from equity financing lead to non-compliance across major standards. No inclusion in Shariah indices reflects these issues, though the healthcare focus aligns with Islamic values of preserving life. Purification is required for any impure income, and investors should monitor financial maturation post-commercialization. Overall, the stock is non-compliant with moderate quality due to financial concerns.